Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	80.82M 8.03M 7.22M 6.73M 6.1M 11.46M 764M 11.53M 31.56M 396M 30.13M 29.48M 1.28B	P/E 2026 *	-2.43x	P/E 2027 *	-2.02x
Enterprise Value	72.82M 7.23M 6.5M 6.07M 5.5M 10.33M 688M 10.39M 28.43M 357M 27.15M 26.56M 1.15B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	52.67%	Yield 2026 *	-	Yield 2027 *	-

09-24	Vivesto to present Paccal Vet data at conference	FW
09-24	Vivesto AB Presents Paccal Vet Data At The Veterinary Cancer Society Annual Conference 2026	CI
09-17	Vivesto sees tumor effect with Paccal Vet in cat study	FW
09-17	Vivesto reports positive topline results from the Paccal Vet feline study	FW
09-17	Vivesto Reports Positive Paccal Vet Cat Topline Results Supporting Continued Clinical Development	CI
09-15	Vivesto reports positive topline results in pilot dog study (update)	FW
09-15	Vivesto reports positive topline results in pilot dog study	FW
09-15	Vivesto AB Reports Positive Topline Results from Clinical Pilot Study Evaluating Paccal Vet in Dogs with Splenic Hemangiosarcoma Following Splenectomy	CI
08-13	Vivesto narrowed its loss in the second quarter, CEO says: we are staying on plan	FW
08-13	Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Calendar for Thursday, August 13	FW
07-07	Vivesto chairman Peter Zonabend increases his shareholding	FW
07-01	Vivesto Completes Enrollment in Cat Study of Paccal Vet	FW

05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
11-21	DNB Carnegie Lowers Target Value for Vivesto Following Rights Issue Announcement	FW
25-08-13	DNB Carnegie Lowers Target Value for Vivesto as Costs Expected to Remain Steady	FW
24-07-09	Paccal Vet analysis could raise the temperature for Vivesto - Penser	FW
22-12-30	Orrön Energy the year's best and Isofol Medical the year's worst share on Nasdaq Stockholm	FW

09-24	Vivesto presents Paccal Vet data at the Veterinary Cancer Society Annual Conference 2026	AQ
09-17	Vivesto: Positive top-line results in cat study	AQ
09-17	Vivesto reports positive Paccal Vet cat topline results supporting continued clinical development	AQ
09-15	Vivesto: Positive top-line results in dog study	AQ
09-15	Vivesto’s positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet	AQ

20-03-25	Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
20-01-30	Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves

Vivesto AB Stock OTC Markets

Stocks

OASMY

US67421W1099

Pharmaceuticals

Valuation: Vivesto AB

Chart: Vivesto AB

Latest news: Vivesto AB

Last Transcript: Vivesto AB

Analysts' recommendations: Vivesto AB

Press Releases: Vivesto AB

News in other languages: Vivesto AB

Managers and Directors: Vivesto AB

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Erik Kinnman CEO	Chief Executive Officer	68	2023-01-22
Björn Svanström DFI	Director of Finance/CFO	55	2026-06-30
Teresa Fernandez Zafra CTO	Chief Tech/Sci/R&D Officer	39	2022-12-31

Director	Title	Age	Since
Isak Peter Zonabend CHM	Chairman	46	2022-05-24
Hege Hellstrom BRD	Director/Board Member	61	2019-09-25
Pål Ryfors BRD	Director/Board Member	43	2022-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVESTO AB	-.--%	-99.00%	-	-	8.1M
ELI LILLY AND COMPANY	+4.05%	+2.05%	+49.34%	+96.73%	1,040B
JOHNSON & JOHNSON	+1.50%	-2.67%	+31.81%	+59.68%	599B
ABBVIE INC.	+3.47%	+4.39%	+23.63%	+92.40%	485B
MERCK & CO., INC.	+3.82%	+3.07%	+73.75%	+41.32%	350B
ROCHE HOLDING AG	+3.09%	+3.03%	+29.59%	+47.09%	345B
NOVARTIS AG	+2.82%	+2.20%	+17.90%	+40.67%	272B
ASTRAZENECA PLC	+3.40%	+0.99%	-3.44%	+12.10%	244B
AMGEN INC.	+3.20%	+3.00%	+44.79%	+48.31%	223B
GILEAD SCIENCES, INC.	+2.83%	+3.39%	+28.15%	+91.70%	183B
Average	+2.79%	+2.38%	+32.84%	+58.89%	415.87B
Weighted average by Cap.	+3.19%	+2.31%	+36.62%	+67.73%

	2026 *	2027 *
Net sales	-	-
Net income	-31M -3.08M -2.77M -2.58M -2.34M -4.4M -293M -4.42M -12.1M -152M -11.56M -11.31M -489M	-40M -3.97M -3.57M -3.33M -3.02M -5.67M -378M -5.71M -15.62M -196M -14.91M -14.59M -631M
Net Debt	-8M -794K -714K -667K -604K -1.13M -75.61M -1.14M -3.12M -39.24M -2.98M -2.92M -126M	-17M -1.69M -1.52M -1.42M -1.28M -2.41M -161M -2.43M -6.64M -83.38M -6.34M -6.2M -268M